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ABSTRACT 
Phosphorous (P) is essential to bone growth and maintenance; however, little 
research has focused on the genetic mechanisms controlling P utilization. Thirty-six pigs 
from two sire lines known to differ in bone structure (heavier-boned, HB, and lighter-boned, 
LB) were assigned to three diets (P adequate, P repletion, or P deficient). After 14d, bone 
marrow and intact radial bones were collected. Based on dietary treatment, we observed 
differences between these lines in growth rate, bone integrity, and gene expression within 
bone marrow. In HB, but not LB pigs, the P deficient diet caused a decrease in weight gain 
(P<0.01). For both lines, P deficiency caused a reduction in radial bone strength (P<0.01), 
but HB P deficient animals had greater (P<0.10) bone integrity than LB P deficient pigs. In 
HB, but not LB pigs, dietary treatment affected the expression of CALCR (P<0.05), VDR 
(P<0.04), IGFI (P<0.11), and IGFBP3 (P<0.06). There was also a trend of increased IL6, 
TFIIB, and SOX9 expression with P deficiency in HB, but not LB, pigs. A trend of 
increased expression of OXTR was seen in P deficient animals in both genetic backgrounds. 
Expression of RAN KL, BG LAP, 0 PG, ARAF I, and JG FBP 5 was not affected by genetic 
background or diet. These data suggest that HB pigs were more responsive to dietary P 
restriction than LB pigs. Differences in growth rate, bone integrity, and gene expression 
within the bone marrow suggest a difference in the homeorhetic control of P utilization 
between these genetic lines. Linkage analysis of the VDR HpyCH4IV polymorphism in the 
Berkshire x Yorkshire intercross family mapped VDR to pig chromosome Sq. The genes 
that were differentially expressed based on genetic background and dietary treatment 
interaction were then examined for single nucleotide polymorphisms (SNPs). We identified 
SNPs in CALCR, VDR, JGFBP3, and OXTR genes, and PCR restriction fragment length 
Vl 
polymorphism (PCR-RFLP) tests were developed using restriction enzymes Bann, 
HpyCH4IV, Bsam, and Aval, respectively. These polymorphisms were associated with 
several growth performance measurements, including feed: gain, average daily feed intake, 
and average daily gain. Most interestingly, the CALCR Bann polymorphism showed 
significant associations with bone strength. Understanding the interaction between nutrition 
and genotype that optimize bone integrity could lead to novel treatments for osteoporosis 
and aid in the development of tests for identifying those at risk before peak bone mineral 
density has been achieved. This new knowledge could also lead to genotype-specific dietary 
intervention strategies which will likely be more effective in reducing the incidence of 
osteoporosis. 
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CHAPTERl:GENERALINTRODUCTION 
Introduction 
Osteoporosis is a multi-factorial skeletal disease that is characterized by low bone 
mineral density (BMD) and bone integrity, with a consequent increase in bone fragility and 
susceptibility to fracture. There are currently more than 10 million Americans with 
osteoporosis and an additional 34 million with low bone mineral density, which puts them at 
risk for osteoporosis [1]. In the U.S. alone, over 1.5 million fractures are attributed to 
osteoporosis annually, and these injuries translate into enormous medical expenses, with an 
estimated national direct expenditure (hospitals and nursing homes) of $14 billion each year 
for osteoporosis and related fractures [1]. Because of the aging of the populous, the number 
of annual fractures and their associated costs could double or triple by the year 2020 [2, 3]. 
Bone mineral turnover occurs throughout life, with rates of deposition exceeding 
rates ofresorption during growth and adolescence. Peak BMD in humans occurs relatively 
early in life with nearly 90% of maximum skeletal mass accumulated by age 18 [ 4]. After 
achieving peak BMD, bone resorption begins to exceed bone formation. Since BMD is used 
to diagnose osteoporosis, the lifetime risk of developing this disease may be established 
during the first few decades of life. Therefore, maximizing peak bone mass (PBM) early in 
life is critical. 
Acquisition of PBM during growth depends on a variety of factors, including 
nutrition and genetics [5, 6]. While many studies have shown an impact of genetics, dietary 
Ca, dietary P, and the Ca to P ratio on skeletal integrity and mineral homeostasis, the 
mechanisms by which genetic background influences nutrient requirements to maximize 
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BMD has not been determined. Understanding these interactions could lead to novel 
treatments for osteoporosis and aid in the development of tests for identifying those at risk 
for this disease. 
Thesis Organization 
This thesis consists of a general introduction to the topic, a literature review, two 
journal articles, and a general conclusion. The journal articles are prepared in the style 
appropriate for submission to Bone (Chapter 3) and Animal Genetics (Chapter 4). 
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CHAPTER 2: LITERATURE REVIEW 
Introduction 
Osteoporosis is a multi-factorial skeletal disease that is characterized by low bone 
mineral density (BMD) and bone integrity, with a consequent increase in bone fragility and 
susceptibility to fracture. There are currently more than 10 million Americans with 
osteoporosis and an additional 34 million with low BMD which puts them at risk for 
osteoporosis [1]. Osteoporosis affects an estimated 75 million people in Europe, the U.S., 
and Japan [2]. In the U.S. alone, over 1.5 million fractures are attributed to osteoporosis 
annually, including 300,000 hip fractures, 700,000 vertebral fractures, 250,000 wrist 
fractures, and more than 300,000 fractures at other sites [1]. These injuries translate into 
enormous medical expenses, with an estimated national direct expenditure (hospitals and 
nursing homes) of $14 billion each year for osteoporosis and related fractures [ 1]. Because 
of the aging of the populous, the number of annual fractures and their associated costs could 
double or triple by the year 2020 [3, 4]. 
Diagnosing Osteoporosis 
Although not perfectly correlated with fracture risk, reduced BMD is currently used 
to diagnose osteoporosis. A patient's BMD is compared to the average peak BMD of young 
adult women, and then expressed as a T-score. Bone mineral density measurement is a 
widely available noninvasive method of identifying individuals with osteoporosis and, 
possibly, those at high risk for fracture. In addition, studies have found a strong inverse 
relationship betweenBMD and incidence of fracture in postmenopausal women [5, 6]. 
However, BMD is only one of many contributors to bone strength and fracture risk, and 
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there is increasing evidence that it is not the best predictor of bone integrity (fracture 
resistance) [7, 8, 9]. Bone strength is derived from both bone quantity and bone quality. 
Bone quantity consists of both density and size, which together constitute mass. Bone 
quality consists of structural (micro- and macroarchitecture) and material properties, as well 
as the balance between bone production and resorption. Changes in bone turnover markers 
may be a more accurate predictor of fracture risk. There are several bone biochemical 
parameters that reflect bone formation and resorption. Serum markers of bone formation 
related to the osteoblast activity include osteocalcin, procollagen type I carboxy-terminal 
propeptide, total alkaline phosphatase, and bone-specific alkaline phosphatase. Urinary 
markers of bone resorption from breakdown of bone tissue include calcium, pyridinoline, 
and deoxypyridinoline. 
Preventing Osteoporosis 
Once osteoporosis is diagnosed, treatment depends mainly on drugs that inhibit bone 
resorption, either directly or indirectly. Reversing osteoporosis once the disease has 
developed has had extremely limited success [10]. The frequency and severity of 
osteoporosis coupled with the difficulty in reversing the disease once it has developed has 
focused a great deal of research on developing methods for its prevention. 
The Importance of Attaining Peak Bone Mass 
Osteoporosis is generally considered a geriatric disorder, although premature 
osteoporosis is a growing concern in female athletes and hysterectomy patients [11, 12]. 
Since osteoporosis is diagnosed by low BMD and the majority of bone mass is developed 
during the adolescent and young adulthood years and BMD at maturity is an important 
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determinant of the amount of residual bone mass present in later years, osteoporosis can be 
considered a pediatric disease with elderly onset. The precise age at which peak bone mass 
(PBM) is attained is not known, but studies have estimated that it occurs between 16 and 30 
y of age [ 13, 14, 15]. It is generally accepted that the loss of PBM begins as early as the 
third decade of life [16]. Peak bone mass is highly correlated to the risk of osteoporosis [13, 
17, 18]. Failure to achieve optimal bone mass therefore presents a significant risk for 
developing osteoporosis later in life, and optimizing PBM may decrease the prevalence of 
osteoporotic fractures. It is now commonly accepted that individuals with higher PBM 
achieved during adolescent years will be at lower risk for developing osteoporosis later in 
life [13, 17]. 
Achieving and maintaining PBM depends on a variety of factors including nutrition, 
genetics, and environment [19]. In addition, physical activity, chronic illness, and 
medications are childhood factors that may affect PBM [20] . Bone acquisition is 
accelerated within a given genetic potential by lifestyle choices, including diet, eating 
behavior, exercise, and smoking [21]. 
Bone formation and Metabolism 
Bone is generally classified into two types: cortical bone, also known as compact 
bone, and trabecular bone, also known as cancellous or spongy bone. Cortical bone is found 
primarily in the shaft of long bones and forms the outer shell around cancellous bone at the 
end of joints and the vertebrae. Trabecular bone is found in the end of long bones, in 
vertebrae, and in flat bones like the pelvis. The bone matrix is composed of numerous non-
collagenous proteins. Collagen makes up 90% of bone protein and gives lamellar bone its 
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structure [22]. Anionic complexes found on collagen fibers, which have a high ion binding 
capacity, are thought to play an important role in calcification. 
Bone is a highly dynamic tissue that is constantly undergoing mineral deposition and 
resorption. Linear growth in long bones occurs at epiphyseal growth plates. These plates 
are between the epiphyses and diaphysis of the bone. Columns of chondrocytes on the 
epiphyseal side divide continuously causing this growth. As the collagen layer thickens, 
older collagen calcifies and older chondrocytes deteriorate. Osteoblasts lay down a bone 
matrix on top of a cartilage base. The shaft lengthens as new bone is added at the ends. As 
long as the epiphyseal plate is active, long bone growth continues. Appositional growth 
occurs from the deposition of new bone on the periosteal surfaces, accompanied by 
resorption from the endosteal surfaces. 
Bones develop either by endochondral ossification or intramembranous ossification. 
Any growth following these types of development consists of remodeling [23]. Bone 
remodeling is a dynamic process of continuous formation and destruction (resorption) that is 
dependent on two major cell types: osteoclasts and osteoblasts. Osteoclasts are responsible 
for the removal of old bone, while osteoblasts deposit the new bone. The purpose of 
remodeling is to allow the bone to adapt to changes in distribution of mechanical forces and 
to repair microdamage. Bone remodeling also occurs in order to maintain calcium and 
phosphorous homeostasis. 
On average, the skeleton remodels about three times during a person' s lifetime [24]. 
In normal adult bone, formation of new bone by osteoblasts matches resorption of old bone 
by osteoclasts. Although there is less trabecular bone than cortical bone in the skeleton, 
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trabecular bone turns over 3-10 times faster than cortical bone and is, therefore, more 
sensitive to changes in bone resorption [25] . The rate of bone remodeling can differ due to 
physical loading, proximity to a synovial joint, or presence of haemopoietic tissue in 
adjacent bone marrow [26]. 
Bone remodeling follows an ordered sequence of events. During bone resorption, 
osteoclasts are recruited, and the matrix is exposed by proteinases derived from bone lining 
cells. Osteoclasts then act on the matrix and create a resorptive pit (known as Howship's 
lacuna). Lysosomal enzymes are released through an osteoclast border into pockets causing 
matrix resorption, and bone formation begins. During bone formation, osteoblasts fill the 
lacuna with osteoid that is mineralized to form new bone matrix [25]. When this process is 
under normal homeostatic control, the amount of bone resorbed is roughly equal to the 
amount of new matrix formed. Thus, this process causes a zero net loss of bone mineral in 
healthy adults. Changes in the quality or quantity of bone arise from disorders of bone 
modeling during growth or remodeling during adult life. 
Chondrocytes 
Chondrocytes are the cells responsible for the production of cartilage. Endochondral 
bone development is a complex process in which undifferentiated mesenchymal cells 
differentiate into chondrocytes, which then undergo well-ordered and controlled phases of 
proliferation, hypertrophic differentiation, death, blood vessel invasion, and finally 
replacement of cartilage with bone. The sum of the results of the proliferative and 
hypertrophic phases of growth plate chondrocytes is the physical lengthening of the bone 
[27]. The cells of the growth plate are organized into columns that run parallel to the growth 
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axis. The Indian hedgehog/parathyroid hormone related peptide feedback loop regulates the 
entry of chondrocytes into the hypertrophic phase of growth [28, 29]. Regulatory pathways 
intrinsic to the growth plate allow for different growth rates of individual growth plates 
within a single skeleton. In this way, the growth plates of the tibia can grow very fast while 
the smaller bones of the hand grow more slowly, despite the same systemic exposure. Sex 
determining region Y-box 9 (SOX9) is a transcription factor that has an essential role in 
chondrocyte differentiation. Studies of conditional knockouts [30] have shown that SOX9 is 
required for formation of normal mesenchymal condensations, for conversion of 
mesenchymal cells to chondrocytes, for proliferation of chondrocytes, and for suppression of 
premature conversion of these chondrocytes to hypertrophic chondrocytes. The 
identification of SOX9 mutations in campomelic dysplasia, a severe dwarfism syndrome 
characterized by abnormalities in all skeletal elements derived from cartilage, suggests a role 
for SOX9 in endochondral bone development [31, 32]. In addition, it has been shown that 
SOX9 regulates the transcription of type II collagen, a chondrocyte-specific gene, by binding 
to an enhancer and activating it [33, 34]. 
Osteoblasts 
Bone formation is carried out by mesenchyme-derived osteoblasts. Osteoblasts 
within trabecular bone probably differentiate from stromal cell precursors in bone marrow, 
and manufacture a complex extracellular matrix, which subsequently mineralizes [35]. 
Osteoblasts secrete enzymes which facilitate mineral deposition within the matrix. Many 
growth factors affect bone formation, including insulin-like growth factors (IGFs). IGFl is 
a growth-promoting polypeptide that is essential for normal growth and development, and 
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IGFl has been demonstrated to be a differentiation factor for osteoblasts, as well as a 
stimulator of proliferation for chondrocytes, pre-osteoblasts, and fibroblasts [36]. In 
addition, IGFl production is influenced by nutritional status [37]; in general, malnutrition 
reduces circulating IGFl levels markedly. The biological activity oflGFl is modulated by 
specific binding proteins (IGFBPs), which bind and regulate the access ofIGF to its 
receptor. Osteoblasts themselves are capable of producing a wide array of factors that can 
potentially act as autocrine and paracrin regulators of bone cell function. Several cytokines 
that can be produced by stromal cells and osteoblasts, such as receptor activator of nuclear 
factor-kappaB ligand (RANKL) and interleukin-6 (IL6), affect osteoclast recruitment. 
RANKL is an important cytokine for osteoclast differentiation that is stimulated by factors 
that induce bone resorption [38]. Mice without RANKL or its osteoclastic receptor, receptor 
activator ofNF-kappaB (RANK), lack osteoclasts and have severe osteopetrosis [39, 40] . 
IL6 has also been shown to be produced by osteoblasts [ 41]. Injections of an IL6-
neutralizing antibody to gonadectomized mice have been shown to prevent increases in 
osteoclastogenesis in the bone marrow [ 42], and estrogen loss results in an IL6-mediated 
stimulation of osteoclastogenesis [43]. In addition, the level ofIL6 in the serum has been 
shown to be predictive of bone loss in early postmenopause [44]. Serum osteocalcin 
(BGLAP) is considered a marker of bone formation. BGLAP is an extracellular matrix 
protein that inhibits osteoblast function. The location of osteocalcin at bone-forming 
surfaces [ 45, 46] and the increased bone mineralization observed in BG LAP knockout mice 
[ 4 7] and warfarin-treated rats [ 48, 49] supports a role for osteocalcin in suppression of bone 
mineralization. Alternatively, BGLAP has been suggested to increase bone resorption by 
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acting as a chemoattractant for osteoclasts [46, 50]. Polymorphisms in the promoter region 
of the human BGLAP gene have been shown to be associated with BMD [51] . 
Osteoclasts 
Bone resorption is carried out by haematopoietically-derived osteoclasts. The 
concept that osteoclast precursors are of monocyte lineage was suggested by the capacity of 
granulocyte-macrophage precursors to differentiate into osteoclasts in vitro [52] and by 
reports that cultures of peripheral-blood monocytes can differentiate into osteoclasts [53] . 
Osteoclasts differentiate from haematopoietic stem cell precursors under the direction of 
factors that include cytokines, specific interleukins, and other mediators. Their number and 
activity is determined by cell lineage allocation, proliferation, differentiation of osteoclast 
precursors, and the resorptive efficiency of mature osteoclasts. The RANKIRANKL system 
is the major regulatory system for osteoclast recruitment and action [54] . Additionally, 
calcitonin acts directly on bone by inhibiting the activity of osteoclasts via calcitonin 
receptors (CALCR) located on their cell surface [55, 56]. The response of osteoclasts to 
calcitonin is related to the amount of CALCR available for binding with calcitonin on the 
osteoclast surface [ 5 7]. 
The Effect of Genetics on Bone 
It has been shown that most major diseases result from the interaction between 
genetic susceptibility and environmental factors , including diet [58]. The examination of 
DNA sequence variation in order to identify genes that influence multifactorial diseases and 
traits will undoubtedly benefit from single nucleotide polymorphism (SNP) research. 
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With advances in molecular techniques, a great deal of research examining the 
genetic contribution to BMD has been conducted. Numerous studies comparing bone 
mineral mass in mono- and dizygotic twins, or in parents and offspring, have shown a strong 
genetic effect on peak bone mineral mass [5, 59, 60]. In fact, Ferrari et al. (1998) found that 
familial resemblance for most bone traits is present between daughters and their mothers 
before puberty (by the age of 8 yr), particularly at sites of prevailing trabecular bone [61]. 
They concluded that the genetic susceptibility to osteoporosis may already be detectable in 
early childhood. 
Theoretically, genetics could affect the development of osteoporosis in at least two 
ways. Genetic factors could influence the amount of bone mass attained at maturity, and 
individuals with genetically-determined low bone mass might then be more susceptible to 
develop osteoporosis after entering the period of age-dependent bone loss. Alternatively, or 
in conjuction with the above, genetic factors could influence the rate of bone loss, and 
individuals with a genetically-determined accelerated bone loss would be more susceptible 
to developing osteoporosis. 
In one of the largest whole genome scan studies conducted to identify quantitative 
trait loci (QTL), Shen et al. (2004) identified two promising regions on human chromosome 
11 and X that may be used explain some of the variation in BMD [62]. Several candidate 
genes, such as low-density lipoprotein receptor- related protein 5 (LRP 5), bone 
morphogenetic protein 2, matrix metalloproteinase 8 and 13, identified by other researchers 
[63, 64, 65] as being important in accounting for variation in BMD are mapped to these 
regions. Surprisingly, other genes shown to play a key role in the genetic regulation of 
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BMD, such as growth hormone, estrogen receptor, and vitamin D receptor (VDR) [66, 67, 
68], do not map to these regions. 
Polymorphisms in the human CALCR, VDR, IL6, and LRP 5 genes have been shown 
to be associated with BMD and bone metabolism [69-80]. Genetic variation (a 
polyadenosine repeat) in the human VDR gene has been shown to be associated with BMD 
in premenopausal Swedish women [69], and significant association between the VDR 
genotype and osteoporosis in Chinese women has also been observed [70]. Additionally, a 
polymorphism in the VDR gene has been associated with BMD in men [71]. Several allelic 
variants have been identified in the IL6 gene promoter region [72, 73], and polymorphisms 
in the IL6 gene have also been shown to be associated with BMD in some populations [74, 
76]. Polymorphisms in the human CALCR gene have been shown to be associated with low 
BMD and susceptibility to osteoporosis in postmenopausal women [77, 78, 79]. A mutation 
in the gene that encodes the LRP 5 has recently been associated with increased bone density 
[80]. The LRP 5 gene encodes a protein produced by osteoblasts that serves to increase bone 
mass; defects in both alleles of LRP 5 cause an autosomal recessive disorder called the 
osteoporosis- pseudoglioma syndrome, in which the susceptibility to fractures is due to very 
low bone mass [81]. In contrast, there is an autosomal dominant condition in which a gain-
of-function mutation in the N-terminal of one allele of the LRP5 gene results in excess bone 
density [80, 82]. It is therefore believed that mutations within the LPR5 gene are primarily 
responsible for type I autosomal dominant osteopetrosis [80], in which bone density is 
increased, especially in the cranial vault, with a relatively low risk of fractures [83, 84]. 
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However, conflicting results have been reported on the association between BMD 
and polymorphisms of several genes. Despite the correlation of polymorphisms in the genes 
discussed above, these variations are not correlated with BMD in all populations. In a 
Chinese population study, five commonly used markers of four prominent BMD candidate 
genes (collagen type 1 alpha 1, IL6, glucocorticoid receptor, and the transforming growth 
factor beta-1) were examined for the purpose of identifying useful genetic markers for 
osteoporosis genetic research in Chinese. These researchers found that variant alleles of the 
five markers are absent or too rare to be useful genetic makers in Chinese, despite the fact 
that they have been commonly used as polymorphic markers in osteoporosis genetic 
research in other populations [85] . In another study, three SNPs in the VDR gene locus (i.e., 
for BsmI, ApaI, and TaqI) were found to not be associated with BMD [86]. In a large-scale 
population-based study of elderly people, only a small effect of the VDR genotype on BMD 
was found, and the researchers suggested that the weak association that they did find for 
some of the SNPs may be caused by linkage between VDR and another nearby bone-
metabolism related gene [87] . 
Linkage analysis and association studies with numerous DNA markers (single 
nucleotide polymorphisms or microsatellites) have analyzed several bone-related candidate 
genes encoding CALCR, VDR, estrogen receptor alpha, insulin growth factor I, collagen 
type I alpha 1 chain and others [78, 88-92]. Despite this, one definite polymorphic marker 
has not been found to be informative in all populations, which reflects the divergent results 
of association studies with their frequent limitations, the confounding effects of other factors 
such as nutrition, and probably the fact that many of the relevant polymorphisms are still 
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awaiting identification. Once the genetic determinants can be defined, the clinical 
implications would be extensive both in diagnostics and in pharmacogenetics. 
The Effect of Nutrition on Bone 
In addition to the research examining the genetic component of maximal BMD, a 
great deal of research has examined the role of nutrition on BMD since nutrition plays an 
important role in promoting and maintaining bone mass. Nutrition is also an easily 
modifiable factor in the development and maintenance of bone mass and the prevention and 
treatment of osteoporosis. Many studies have focused on older adults who are at high risk 
for osteoporosis. Recently, studies are investigating the influence of nutrition in children 
and young adults. In a 7-y study with females aged 8-13 y, Matkovic et al. (2005) found 
that calcium supplementation positively influenced bone mass acquisition throughout the 
bone-modeling phase of the pubertal growth spurt [93]. Although most nutritional studies 
on bone development have focused on calcium intakes, phosphorous (P) is also essential in 
supporting bone growth and maintenance. However, dietary P requirements are generally 
not of great concern in adolescent girls because average P intakes approximate the 
requirements [94]. Phosphorous is widely distributed in foods including meat, poultry, fish, 
eggs, dairy products, nuts, legumes, cereals, grains, and cola beverages. It is also added in 
processed foods. Phosphorous depletion by diet is unusual, and when it does occur, rickets 
ensue. 
An adjusted P balance depends on dietary P supply, the bioavailability of this 
element in the diet, and on its absorption rate in the gastrointestinal tract. In pigs, most of 
the inorganic P is absorbed in the small intestine by an active transport mechanism under the 
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regulatory control of 1,25-dihydroxy vitamin D mediated system. Approximately 85% of 
the body's Pis found in bone tissue, where it binds with calcium to form the mineral 
hydroxyapatite, which confers strength and rigidity to bones [95, 96]. 
While dietary requirements for calcium and phosphorous to allow normal bone 
growth and development have been known for nearly a century [97], the mechanisms by 
which these nutrients are involved in maximizing BMD have only begun to be elucidated 
[98, 99, 100]. The improvement in BMD with Ca supplementation to deficient diets has 
been shown frequently [101], and the benefit of higher P intakes on bone mineral acquisition 
where Ca is limiting was first suggested by Teegarden et al. (1998) [102]. While 
conclusions that can be drawn from this study alone are limited due to the limitations of self-
reported food intakes used in this study, it brought greater attention to the importance of 
dietary P to bone health. Shapiro and Heaney (2003) demonstrated the importance and 
interdependence of dietary Ca and P for bone growth and integrity in rats [103]. While this 
study provides the advantage of both BMD and bone strength analysis, care must be taken in 
extrapolating these results to humans due to the animal model used. Additionally, while this 
study demonstrated the importance of both dietary Ca and P and the interaction between 
these nutrients, the mechanisms by which these impact bone growth and integrity were not 
elucidated. Masuyama et al. (2003) demonstrated that the ratio of dietary Ca to P impacts 
bone mineralization and turnover in VDR knockout mice by affecting Ca and P intestinal 
transport [104]. Dietary P has also been shown to affect sodium-phosphorous co-transport 
in the intestines of VDR knockout mice [105]. 
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Several trace elements, particularly copper (Cu), manganese (Mn) and zinc (Zn), are 
also essential in bone metabolism as cofactors for specific enzymes. It has been known for 
at least three decades that several trace minerals, particularly magnesium (Mg) and zinc 
(Zn), are essential for organic bone matrix synthesis [ 106). In addition, studies in rats have 
shown that low-level lifetime exposure to cadmium (Cd) diminishes the accumulation of 
bone mass during skeletal growth and influences bone metabolism at maturity [ 107). 
Interaction of Nutrition and Genetics 
These studies clearly show an impact of genetics, dietary Ca, dietary P, and the Ca to 
P ratio on skeletal integrity and mineral homeostasis. However, the mechanisms by which 
genetic background influences nutrient requirements to maximize BMD has not been 
determined. 
Several researchers have begun to examine the interactions of genotype and nutrition 
and the impact these have on BMD. A relationship between VDR genotype, nutrition, and 
BMD in young adult males has been demonstrated [108). A polymorphism in the VDR gene 
was shown to influence the effect of dietary Ca on BMD in the elderly [109), and in 2001, 
Rapuri et al. found an interaction between the VDR genotype and the deleterious effect of 
caffeine on bone [110). In 2003, Opotowsky and Bilezikian found an interaction between 
genetics (racial background) and the effect of early milk consumption on peak and 
postmenopausal BMD [111). Ferrari et al. (2004) demonstrated an interaction between 
dietary Ca level and IL6 genotype on BMD [112]. Kurabayshi et al. (2004) also examined 
the interaction of VDR and estrogen receptor polymorphisms and dietary Ca on BMD [11 3). 
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While these studies have provided the initial "proof of concept" that the interaction 
of nutrition and genetics affect BMD, far more work is needed to elucidate the interactions 
between nutrition and genetics which impact BMD. In 2002, McGuigan et al. found that 
PBM is regulated by an overlapping but distinct set of environmental and genetic factors 
that differ in men and women [114]. Much of the variance observed in BMD was not 
explained by polymorphisms of the VDR, estrogen receptor, collagen type Ial genes in 
relation to other factors such as birth weight, lifestyle diet, and exercise. Therefore, they 
also suggested that either most of the genes that regulate BMD remain to be discovered or 
that major environmental influences on BMD exist that have not yet been identified. 
An underlying difficulty with identifying the mechanisms by which genetic 
background influences the attainment of peak BMD and the prevention of osteoporosis is the 
complexity of the biological processes involved and the confounding factors encountered in 
different studies such as ethnic background, nutrition, and other environmental factors. 
While some work as begun to examine the interaction between different genotypes and 
nutrition and how this influences BMD [ 108, 109, 112, 115], these studies have all focused 
on single candidate genes and limited nutritional interventions. 
In conclusion, the research reviewed in this section clearly demonstrates the need to 
identify the mechanisms by which dietary P interacts with genetic background to affect 
BMD and bone integrity because the lack of this knowledge is preventing the development 
of dietary intervention strategies for the prevention of osteoporosis. Understanding these 
interactions could lead to novel treatments for osteoporosis and aid in the development of 
tests for identifying those at risk for this disease. 
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CHAPTER 3. GENETIC BACKGROUND INFLUENCES METABOLIC 
RESPONSE TO DIETARY PHOSPHORUS RESTRICTION 
A paper submitted to Bone 
Laura J. Hittmeier1'2, Laura Grapes1, Renae L. Lensing1, Max F. Rothschild1, Chad H. 
Stahl1'3 
Abstract 
Phosphorous (P) is essential to bone growth and maintenance; however, little 
research has focused on the genetic mechanisms controlling P utilization. Understanding the 
interactions between genetics and dietary P that optimize bone integrity could provide novel 
interventions for osteoporosis. Thirty-six pigs from two sire lines known to differ in bone 
structure (heavier-boned, HB, and lighter-boned, LB) were assigned to three diets (P 
adequate, P repletion, or P deficient). After 14d, bone marrow and intact radial bones were 
collected. We observed differences between these lines in growth rate, bone integrity, and 
gene expression within bone marrow. In HB, but not LB pigs, the P deficient diet caused a 
decrease in weight gain (P<0.01). For both lines, P deficiency caused a reduction in radial 
bone strength (P<0.01), but HB P deficient animals had greater (P<0.10) bone integrity than 
P deficient LB pigs. In HB, but not LB pigs, dietary treatment affected the expression of 
CALCR (P<0.05), VDR (P<0.06), IGFJ (P<0.11), and IGFBP3 (P<0.06). There was also a 
trend of increased IL6, TFIIB, and SOX9 expression with P deficiency in HB, but not LB, 
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pigs. A trend of increased expression of OXTR was seen in P deficient animals in both 
genetic backgrounds. Expression of RANKL, BG LAP, OPG, ARAF 1, and JGFBP 5 was not 
affected by genetic background or diet. The HB pigs were more responsive to dietary P 
restriction than LB pigs. Differences in growth rate, bone integrity, and gene expression 
within the bone marrow suggest a difference in the homeorhetic control of P utilization 
between these genetic lines. Understanding these differences could lead to novel treatments 
for osteoporosis and aid in the development of tests for identifying those at risk for this 
disease. 
Keywords: Bone, Gene Expression, Phosphorous, Pigs, Osteoporosis 
Introduction 
Currently, in the U.S. alone, 10 million individuals suffer from osteoporosis and an 
additional 34 million have been diagnosed with low bone mass, placing them at increased 
risk for this disease [ 1]. Osteoporosis is characterized by a decrease in bone mineral density 
(BMD) and deterioration of the microarchitecture of bone, both of which result in increased 
susceptibility to fractures. Over 1.5 million fractures are attributed to osteoporosis annually, 
including 300,000 hip fractures, 700,000 vertebral fractures, 250,000 wrist fractures, and 
more than 300,000 fractures at other sites [1] . These injuries translate into enormous 
medical expenses, with an estimated national direct expenditure (hospitals and nursing 
homes) of $14 billion each year for osteoporosis and related fractures [ 1] . Because of the 
aging of the populous, the number of annual fractures and their associated costs could 
double or triple by the year 2020 [2, 3]. 
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Bone mineral turnover occurs throughout life, with rates of deposition exceeding 
rates of resorption during growth and adolescence. Peak BMD in humans occurs relatively 
early in life with nearly 90% of maximum skeletal mass accumulated by age 18 [ 4]. After 
achieving peak BMD, bone resorption begins to exceed bone formation. Since BMD is used 
to diagnose osteoporosis, the lifetime risk of developing this disease may be established 
during the first few decades of life. Therefore, maximizing peak bone mass (PBM) early in 
life is critical. 
Acquisition of PBM during growth depends on a variety of factors, including 
nutrition and genetics [5 , 6]. Although most nutritional studies on bone development have 
focused on calcium (Ca), phosphorous (P) is also essential in supporting bone growth and 
maintenance. Phosphorus deficiency can be caused by major alterations in energy 
metabolism, particularly related to weight reduction programs [7] or the consumption of 
vegetarian diets in which a majority of the Pis present as phytic acid (which is of limited 
nutritional value) [8]. A genetic contribution to the acquisition of PBM and the etiology of 
osteoporosis has also been recognized [5] . Genetic linkage studies [9, 1 OJ and candidate 
gene association studies [11 , 12] have implicated several loci and candidate genes in the 
regulation of bone mass and the pathogenesis of osteoporotic fractures. Based on their roles 
in bone growth and development, genes of particular interest include calcitonin receptor 
(CALCR), vitamin D receptor (VDR), insulin-like growth factor 1 (IGFI) , insulin-like 
growth factor binding protein 3 (IGFBP3), insulin-like growth factor binding protein 5 
(IGFBP5), oxytocin receptor (OXTR) , interleukin-6 (IL6) , transcription initiation factor IIB 
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(TFIIB), sex determining region Y-box 9 (SOX9), A-Raf-1 (ARAFJ), receptor activator of 
nuclear factor-kappaB ligand (RANKL), osteoprotegerin (OPG), and osteocalcin (BGLAP). 
Understanding the interactions between genetics and diet that optimize bone integrity 
could provide novel interventions for the prevention of osteoporosis. In this study, we used 
a rapidly growing young pig model to examine the effects of P deficiency and genetic 
background on growth performance, bone strength, and gene expression in bone marrow. 
The phenotypic differences seen in the two lines of pigs used allowed us to examine P 
deficiency x genetic interactions between genetically divergent populations. 
Materials and Methods 
Animals 
All animal protocols were approved by Iowa State University's Committee on 
Animal Care. Thirty-six female piglets of two genetic lines were obtained by crossing two 
sire lines with a single female line. These two sire lines are known to differ in bone 
structure, with one considered heavier-boned (HB) and the other considered lighter-boned 
(LB). All breeding females and semen from the two sire lines were purchased from Pig 
Improvement Company (Franklin, KY). At 21 d of age, the piglets were fed a basal diet that 
met or exceeded their nutritional requirements [13] for 7 days prior to study initiation. At 
the initiation of the study, animals were assigned to one of three treatments based on genetic 
background and initial body weight. These treatments consisted of being fed either a P 
adequate diet (P+ ), a P deficient diet (P-), or the P deficient diet for 7 d followed by the P 
adequate diet for 7d (P repletion diet, RP). The P+ diet consisted of 0.86% Ca, 0. 71 % P Toia1, 
and 0.41 % P Available· The P- diet consisted of 0.52% Ca, 0.43% P rotab and 0.14% P Available· 
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Lower dietary Ca supplementation levels in this treatment group were used to maintain an 
equal Ca:P ratio among all treatments groups. This is necessary since higher Ca:P ratios 
would cause the precipitation of dietary phytate in the gastrointestinal tract thereby 
dramatically reducing the bioavailability of Ca and other minerals that coprecipitate with 
phytic acid. Animals were housed individually in 0.43 m x 1.22 m pens in environmentally 
controlled rooms. Body weights were determined initially and weekly throughout the trial 
and average daily gain was calculated for each week individually and for the two week trial 
period. Individual feed consumption was recorded weekly and used to calculate feed to gain 
ratio for each week and across the trial period. 
At day 0, day 7, and day 14 of the study, venous blood samples were collected into 
Vacutainer Plus tubes containing sodium heparin (BD Vacutainer, Franklin Lakes, NJ) by 
venipuncture. Plasma was obtained by centrifugation at 2,000 x g and 4°C in a Kendro 
SuperT21 Centrifuge (Kendro, Newton, CT) and stored at -20°C until used for analysis. On 
day 14 of the study, after collecting blood samples and recording body weight, all animals 
were euthanized by captive bolt. Intact radial and metacarpal bones were collected, placed 
in individual plastic bags, and stored at 4°C. Bone marrow samples were collected from the 
right humerus and snap frozen in liquid nitrogen. These samples were stored at -80°C until 
RNA extraction. 
Biochemical Analysis 
Calcium concentration, alkaline phosphatase activity (ALP), and inorganic 
phosphorous concentration (PIP) were determined for all plasma samples. Plasma Ca levels 
were determined using a Cole-Palmer Digital Flame Analyzer, model 2655-00 (Cole-Palmer 
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Instrument Co., Chicago, IL). Alkaline phosphatase activity was assayed by the method of 
Bowers and McComb [14], in which the rate of formation of yellow-colored structures by 
the hydrolysis of p-nitrophenol phosphate to p-nitrophenol is proportional to the level of 
ALP activity in the plasma. The rate of appearance of this yellow color was determined at 
700nm in a PowerWave HT microplate scanning spectrophotometer (Bio-Tek, Winooski, 
VT). Inorganic P concentrations were determined by the method of Gomori [ 15] modified 
for use with a microplate spectrophotometer. Briefly, plasma was deproteinated with 12.5% 
tri-chloroacetic acid and assayed using Elon solution (p-methylaminophenol sulfate). 
Bone Measurements 
Within one week following sacrifice of the animals, the radii were manually 
cleaned of all soft tissue and tested for tensile strength using a 5kN Flexure Fixture, 
configured for three-point bend tests, attached to an Instron Universal Testing Machine 
Model 4502 equipped with a 10 kN load cell (Instron Corporation, Canton, MA). Load 
applied at bone breaking was determined using Series IX, v 8.08.00 software (Instron 
Corporation). Metacarpals were stored at -20°C until analysis for bone ash. Ash 
determination was made following an ether extraction by drying the metacarpals at 70°C for 
48h and then ashing the bones in a muffle furnace at 700°C for 48h. 
RNA isolation and cDNA synthesis 
RNA isolation from 30 - 70 mg of bone marrow was performed using the Ambion 
RNAqueous kit (Ambion, Austin, TX). Extracted total RNA was treated with 
deoxyribonuclease I to eliminate genomic DNA (Ambion DNA-free kit) and then reverse 
transcribed with Superscript II (Invitrogen Life Technologies, Carlsbad, CA) according to 
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the manufacture's instructions. The cDNA was then incubated for 20 minutes at 37°C with 
E. coli RNase H and stored at -80°C until analysis by real-time PCR. 
Real-time PCR 
In order to measure specific transcript levels, semi-quantitative real-time PCR was 
performed using the MyiQ™ Single Color Real-Time PCR Detection System (Bio-Rad 
Laboratories, Hercules, CA). Primer oligonucleotides (Table 1) were designed using 
"PrimerQuest" software available from Integrated DNA Technologies, Inc (Coralville, IA). 
Reactions were performed using 12.5 µl of 2X SYBR Green Supermix (Bio-Rad), 50 - 900 
nM of each primer, and 100 ng of the above-described cDNA reaction in a final volume of 
25 µ1. Prior to quantification by real-time PCR, optimal primer concentrations for each 
primer set were determined, and the linearity of amplification for each gene of interest was 
verified to be similar to that of the control gene, 60S ribosomal RNA (RPL35), which was 
verified to not be affected by treatment or genetic background. Additionally, all amplified 
products were sequenced to confirm their identities. The thermal cycling conditions allowed 
for 45 cycles of 30 s of melting at 95°C followed by 30 s of annealing and extension at 60°C. 
After the 45 amplification cycles, all samples were subjected to a melt curve in which they 
were heated at 1°C/30s increments from 60°C to 94°C to validate the absence of non-specific 
products. Normalized gene expression is presented using the T~Ct method [16]. 
Statistical Analysis 
Data were analyzed using the PROC MIXED procedures of SAS (SAS Institute, 
Cary, NC) [17] with genetic background (sire line), treatment and the interaction between 
genetic background and treatment considered as fixed effects. The effect of sow nested 
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within sire line was treated as a random effect. For average daily gain, average daily feed 
intake and feed:gain values, initial body weight was considered as a covariate in the model. 
For bone strength and bone ash values, body weight at week 2 was considered as a covariate 
in the model. Means and standard errors are presented. 
Results 
Growth Performance 
Among the HB pigs, the P deficient group had significantly (P<O.O 1) lower average 
daily gain than the other two treatment groups (Table 2). However, the LB P deficient pigs 
did not exhibit any growth depression when compared to P adequate pigs, and the P 
repletion group tended to have higher (P<O. l) average daily gain than either of the other two 
treatment groups. In addition, the HB P adequate pigs exhibited significantly (P<0.1) higher 
average daily gain than the LB P adequate animals. 
Plasma Assays 
Plasma Ca concentrations were not affected by dietary treatment, genetic 
background, or their interaction (Table 3). Initially, there were no differences in PIP or ALP 
between any of the treatment groups. After 7d on treatment diets, pigs receiving the P 
adequate diet had higher (P<0.01) PIP and lower (P <0.01) ALP than those receiving the P 
deficient diets. At the completion of the study, the P deficient groups had lower (P<0.01) 
PIP and higher (P<0.01) ALP than the other treatments groups, and the P repletion groups 
were able to achieve PIP and ALP similar to those of the P adequate groups. There were no 
genetic background effects or genetic background x treatment interactions for any of these 
plasma indicators of P status. 
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Bone Measurements 
Bone strength and ash percentage were affected by dietary treatment in pigs from 
both genetic backgrounds (Table 4). The radial strength and metacarpal ash percentage of 
the P deficient pigs was significantly lower (P<O.O 1) relative to the other two treatment 
groups. In addition, there was a significant (P<O. l) genetic background x treatment 
interaction in bone strength among the P deficient pigs. The P deficient HB pigs exhibited 
significantly stronger radial bones than the LB P deficient pigs. We did not observe any 
genetic background x treatment interactions for metacarpal ash percentage. 
Real-Time PCR 
Calcitonin Receptor (CALCR) 
Levels of CALCR mRNA were significantly affected by dietary treatments among 
the HB, but not LB, pigs (Fig. 1 ). The P deficient HB pigs had increased levels of CALCR 
message when compared to both the P adequate and P repletion groups (P<0.05 and 0.02, 
respectively). The P deficient HB pigs also had significantly higher (P<0.08) concentrations 
of CALCR transcript than the P deficient LB pigs. Additionally, the HB P repletion pigs had 
lower (P<0.05) CALCR mRNA levels than the LB P repletion group. Although the level of 
CALCR mRNA was affected by the interaction between genetic background and dietary 
treatment in both the P deficient and repletion groups, it was not affected by this interaction 
in the P adequate group. 
Vitamin D receptor (VDR) 
Levels of vitamin D receptor (VDR) mRNA were not affected by dietary treatments 
in LB animals; however, in the HB pigs, P deficiency caused a significant increase in VDR 
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mRNA compared to the P adequate and the P repletion groups (P<0.06 and 0.04, 
respectively) (Fig. 2). The level of VDR mRNA was affected by the interaction between 
genetic background and dietary treatment in the P deficient animals. Phosporous deficient 
HB pigs had higher (P<0.05) concentrations of VDR transcript than the P deficient LB pigs. 
However, VDR mRNA levels were not affected by this interaction in the P adequate or 
repletion groups. 
Insulin-like growth factor 1 (IGF 1) and JGF binding protein 3 (IGFBP 3) 
In the LB line, the amount of JGFJ and IGFBP3 messages in bone marrow was not 
affected by dietary treatment (Fig. 3, 4). The P deficient HB pigs had increased levels of 
IGFJ message when compared to both the P adequate and P repletion groups (P<0.11 and 
0.02, respectively). The P deficient HB pigs also had increased levels of JGFBP3 mRNA 
compared to the P adequate and P repletion groups (P<0.06 and 0.03, respectively). The P 
deficient HB animals also had higher (P<0.07) levels of IGFBP3 transcript than the LB P 
deficient animals. 
Oxytocin receptor (OXTR) 
Levels of OXTR mRNA in the bone marrow were not significantly affected by any 
dietary treatments or genetic background (Fig. 5). However, there was a trend (P<0.16) for 
increased transcript concentration in the P deficient pigs compared to the other treatment 
groups. 
Jnterleukin-6 (IL6) , Transcription initiation factor JIB (TFllB), and Sex determining 
region Y-box 9 (SOX9) 
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The amount of interleukin-6 (IL6), transcription initiation factor IIB (TFIIB), and sex 
determining region Y-box 9 (SOX9) messages was not affected by dietary treatment or 
genetic background (Fig. 6, 7, 8). Although not significantly different, there was a trend 
(P<0.20) for increased expression of these genes in the P deficient HB pigs when compared 
to the other HB animals. 
Neither dietary treatments nor genetic background had a significant impact on the 
levels of RANKL, OPG, BGLAP, ARAFI, or JGFBP5 mRNA. 
Discussion 
The objectives of this study were to determine the influence of dietary phosphorous 
(P) on bone metabolism and to examine the effect of genetic background on these responses. 
Plasma Ca concentration, PIP, and ALP were used to validate that our treatment diets were 
effective in producing P deficient animals. In both genetic lines, the feeding of a P deficient 
diet caused a rapid decline in PIP and an increase in ALP. Repletion of PIP as well as a 
return to normal ALP levels was achieved within 1 week by providing deficient animals 
with a P adequate diet. These data indicate that differences in genetic background did not 
have an effect on these traditional indicators of mineral status. 
In HB animals P deficiency caused a significant reduction in average daily weight 
gain; however the LB animals ' growth rate was not affected by P deficiency. Previous 
research has demonstrated both a prompt growth-retarding effect of P deficiency [ 18], as 
well as a lack of this effect [ 19]. While Stahl et al. [ 19] suggested that the lack of a growth 
retarding effect of P deficiency to young pigs may be due to genetic background, to the best 
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of our knowledge, this is the first report demonstrating that genetic background influences 
the growth response to dietary P deficiency. 
In addition to altered growth response to P deficiency, another interesting genetic 
background x dietary P interaction was observed in the P repletion groups. The HB P 
repletion pigs maintained average daily gains that were not significantly different from that 
of P adequate pigs; however, the LB P repletion animals had a higher growth rate than even 
their siblings in the P adequate group. This could indicate a possible up-regulation of a 
phosphate transport system by prior dietary P restriction in these repletion animals. Up 
regulation of P transporter genes in response to dietary P has been described in both rats and 
trout [20, 21]. 
As expected, P deficient pigs had significantly weaker bones than the P adequate or 
the P repletion pigs regardless of their genetic background. However, the P deficient pigs of 
the HB line had significantly (P<O. l 0) stronger bones than the LB P deficient pigs. From 
these data it appears that the HB animals sacrifice their growth rate in order to spare P and 
maintain bone integrity, whereas the LB animals sacrifice bone strength to provide P for 
soft-tissue growth. 
Changes in gene expression within the bone marrow of these animals may help 
explain the altered control of P metabolism seen between these genetic backgrounds. We 
determined that the expression of several genes that have previously been shown to be 
involved in regulating bone turnover are affected by the interaction of genetic background 
and dietary P. The levels of CALCR, VDR, and IGFBP 3 transcripts were increased in the 
bone marrow of P deficient HB pigs but were not altered in the LB animals. These changes 
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further demonstrate a difference in the regulation of P metabolism between these genetic 
backgrounds, as well as provide a possible explanation for the better bone integrity of HB 
pigs during P deficiency. Calcitonin acts directly on bone by inhibiting the activity of 
osteoclasts via calcitonin receptors (CALCR) located on their cell surface [22, 23]. The 
response of osteoclasts to calcitonin is related to the amount of CALCR available for 
binding with calcitonin on the osteoclast surface [24]. In the HB animals, P deficiency 
increased (P<0.05) CALCR expression, which may have inhibited the activity of osteoclasts, 
thereby reducing bone resorption and helping to preserve bone mineral stores. For the LB 
pigs, the expression of CALCR was not affected by P deficiency. This unresponsiveness of 
CALCR message to P deficiency in the LB animals could allow for maintaining normal 
osteoclast function and bone resorption, thereby providing P for soft tissue growth in spite of 
dietary P restriction. A similar increase in VDR message was also seen in HB, but not LB, P 
deficient animals. The P deficient group of the HB line exhibited a significant (P<0.06) 
increase in expression when compared to the other HB pigs. Vitamin D receptor mediates 
most of the actions of vitamin D through transcriptional control of target genes, although the 
importance of VDR to mediate several nongenomic responses to t ie hormonal form of 
vitamin D has also been demonstrated [25, 26]. An increase in tht expression of VDR 
during P deficiency has been shown in other animals [20]. One tn nscriptional effect of 
VDR is the regulation of IGFBP3 expression [27]. 
Insulin-like growth factor binding proteins (IGFBPs) bind to insulin-like growth 
factor 1 (IGFl) with high affinity and specificity. IGFBPs regulat~ the access ofIGFl to its 
receptor, extend the half-life ofIGFl, and transport IGFl to various tissues. IGFBP3 is the 
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most abundant IGFBP; it binds more than 75% of circulating IGF . IGFBP3 expression 
was not affected by dietary treatments in the LB line; however, the P deficient HB animals 
had increased (P<0.06) expression when compared to the other two groups. An increase in 
IGFBP3 in the P deficient HB animals may prevent IGFl from stimulating bone formation 
by binding and sequestering it. 
IGFl is considered to be a potent stimulator of bone formation. Although we did not 
expect to see an increase in IGFI message with P deficiency, the P deficient HB pigs had 
increased levels of IGF 1 message when compared to the other two treatment groups. If the 
increase in IGFBP 3 message also seen in this treatment group corresponded to an increase 
in active IGFBP3, the increase in IGFJ transcripts may be due to cells sensing a functional 
deficiency of IGFl due to its complexing with IGFBP3. 
In addition to these genes that are known to have a direct effect on bone turnover, we 
also examined the expression of genes involved in transcriptional regulation, such as the 
general transcription factor IIB (TFIIB), sex determining region Y-box 9 (SOX9), and A-
Raf-1 (ARAF 1). While the expression of ARAF 1 was not affected by P deficiency or by the 
genetic differences between these pigs, there was a trend for increased SOX9 and TFIIB 
expression in the HB P deficient pigs compared to the other HB animals. Transcription 
factor IIB is one of the ubiquitous factors required for transcription initiation by RNA 
polymerase II. In addition, TFIIB has been shown to interact with the VDR [28]. Sex 
determining region Y-box 9 (SOX9) is a transcription factor that has an essential role in 
chondrocyte differentiation and is required for formation of normal mesenchymal 
condensations, conversion of mesenchymal cells to chondrocytes, proliferation of 
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chondrocytes, and suppression of premature conversion of these chondrocytes to 
hypertrophic chondrocytes [29]. In addition, SOX9 regulates the transcription of type II 
collagen, a chondrocyte specific gene [30, 31]. A role for SOX9 in endochondral bone 
development has also been suggested [32, 33]. This differential expression of these 
transcription factors in response to nutrient deficiency and genetic background deserves 
further examination, as it may help to explain the differences in the regulation of mineral 
metabolism that can be attributed to genetic background. 
Although receptor activator of nuclear factor-kappaB ligand (RANKL), 
osteoprotegerin (OPG), osteocalcin (BGLAP), and insulin-like growth factor-binding 
protein 5 (IGFBP5) are all known to be important proteins involved in bone metabolism [34-
45], in this model we found that the expression of these genes was not affected by P 
deficiency or by the genetic differences between these pigs. This suggests that these genes 
are not responsible for differences in the homeorhetic control of P metabolism in young 
growing pigs. Further research is needed to examine if these genes may be involved in the 
regulation of mineral metabolism at different stages of bone growth and development. 
Differential gene expression, as well as altered growth performance under P 
deficiency, suggests a difference in the mechanisms of homeorhetic control of P between 
these genetic lines. The three most statistically significant changes in gene expression that 
were based on dietary P deficiency and its interaction with genetic background were seen in 
CALCR, VDR, and IGFBP3. Polymorphisms in the human CALCR and VDR genes have 
been shown to be associated with BMD [46-51]. Based on our expression data and other 
support in the literature, CALCR, VDR, and IGFBP3 are good candidates for future studies. 
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There is a great need to develop an animal model for human osteoporosis. Pigs are 
an excellent model for investigating the nutritional factors that may affect bone since the 
bone remodeling cycle in pigs is histologically similar to that of humans, but is more rapid, 
allowing relatively short experimental times. Pigs also possess a definable peak bone mass, 
closely resemble humans in their size, diet, gastrointestinal function, and estrous cycle [ 52-
55]. Additionally, pigs are one of the few animal species in which spontaneous fractures 
have been reported [56] . 
While most nutritional studies on bone growth and development have focused on Ca, 
Pis also essential in supporting bone growth and integrity. While the average adult 
consumption of Pin the U.S. is generally considered adequate, between 10% and 15% of 
older women have intakes ofless than 70% of the recommended daily allowance [57], and a 
1986 survey estimated that only 10% of adults in the U.S. take P-containing supplements 
[58]. Currently, osteoporosis patients are given high-dose Ca supplements that consist of 
carbonate or citrate salts. Although P (in the form of phosphate) makes up more than half of 
the mass of bone mineral, very few dietary supplements contain P [59, 60]. In patients given 
high-dose Ca supplements but not meeting their RDA of P, it is possible that dietary P 
bioavailability will be dramatically reduced due to the formation of insoluble tri-calcium 
phosphate or phytic acid salts in the small intestine [59]. Therefore, the amount of absorbed 
P may be too low to meet the needs for soft tissue growth and new bone mineralization [59]. 
Induced P insufficiency under these circumstances would not only limit bone mineral 
deposition, but also enhance osteoclastic bone resorption [ 61] . Attention to the nutritional 
adequacy of the diets of such patients is necessary if they are to realize the full potential of 
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osteoporosis therapies. For these patients, a Ca-phosphate supplement may be preferable in 
place of the usual carbonate or citrate salts. Studies have found that rats fed P-containing 
salts promoted significantly greater improvement in bone development than rats fed 
supplements with only Ca [60). 
Understanding the interaction between nutrition and genotype could lead to novel 
treatments for osteoporosis and aid in the development of tests for identifying those at risk 
before peak BMD has been achieved. With a better understanding of its effect on bone, 
dietary P requirements could be more precisely defined, and we may be able to identify 
human populations that have different dietary requirements in order to optimize their BMD 
and prevent osteoporosis. This new knowledge could also lead to genotype-specific dietary 
intervention strategies which will likely be more effective in reducing the incidence of 
osteoporosis. 
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Table 1. Primers used for quantification of gene expression by Real-Time PCR. 
Gene Name 
60S Ribosomal Protein (RPL35) 
A-Raf-1 (ARAFI) 
Primer sequences for real-time PCR 
I-AACCAGACCCAGAAAGAGAAC 
II-TTCCGCTGCTGCTTCTTG 
I-ACGAGATGCAAGTGCTCAGGAAGA 
II-GCACCACTGTGTGATGATGGCAAA 
GenBank 
Accession No. 
AY550044 
NM 214329 
Calcitonin Receptor (CAL CR) I-TGCTCATGCCATTACTAGGGCAGT NM 214354 
II-ATGACAGGGCCGTGGATGATGTAA 
Insulin-like growth factor 1 I-TTCGCATCTCTTCTACTTGGCCCT NM 214256 
__ VQf D ____________________________________ !!~~_9-T_~~~~IQI99:9-~IIQIIQ~~-~I __ __ ____ __________________ _ 
Insulin-like growth factor I-ACTCCACTCTA TCCACACCAAGATG AF085482 
-~!1:1_~!1:1_g_P!~!~!!1._~_({Qff!_f D __________ !!~9_T~_<;:_QIQ~I~I9~_Q~~I~9J~_Q ______________________________ _ 
Insulin-like growth factor I-AGCAAGCCAAGATCGAGAGAGACT NM 214099 
-~!1:1_~!1:1_8_P!~!~!!1._~_({9_f_l}_f_~) __________ !!~I~~-9-~II~Irrc;:_r9-~Q9I~~JI~I----- ------------------- -----
Interleukin 6 (JL6) I-ACAGCAAGGAGGTACTGGCAGAAA AF518322 
Osteocalcin (BGLAP) 
Osteoprotegerin (OPG) 
Oxytocin Receptor ( OXTR) 
II-AAGCAGGTCTCCTGATTGAACCCA 
I-CT ACCCAGATCCTCTGGAGCCC 
II-TATGCCATAGAAGCGCCGATAG 
I-AACGGCAACACAGCTCACAAGAAC 
II-TGCTCGAAGGTGAGGTTAGCA TGT 
I-CA TGAACTTGTGCAGCGCTTCCTT 
II-AGACAAAGGTGGACGAGTTGCTCT 
AY150038 
BC030155 
X71796 
Receptor activator of nuclear I-TGGATCACAGCACATCAGAGCAGA NM 003701 
J~~!~-~~~~PR~~- Eg~i:i~_(f!-!!!!_4f:) ______ !!~IQ_QT_~~~~~_9-~99_~~~9!\~I~~~I ________ ___ ____ ___ _______ _ 
SRY (sex determining region Y)- I-AGAAGGAGAGCGAAGAGGACAAGT AF029696 
- ~~-~-?_ (~S?~?) ___ _________________________ !!~~IIQ~_<;::_QIQ~Q_Q~II-:\II~IIQ~I ___ ________ ___ ___ ____ ____ __ _ 
Transcription Initiation factor I-TGAATGTGGCCTGGTTGTAGGTGA NM 001514 
_JJ_I_3 __ ('.ff!!f!_) ______________________________ !!~I~~9:9-I~~~~IIQ_<;:_c;:_~~I~~J~_QT_ _________________________ _ _ 
Vitamin D Receptor (VDR) I-TTGCCAAACACCTCAAGCACAAGG 
II-TGCTCTACGCCAAGATGATCCAGA 
AJ606306 
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Table 2. Effect of dietary phosphorous and genetic background on growth performance of 
young pigs. 
Body Average Average 
Weight Daily Daily 
Initial SE Weight Gain SE Feed Intake SE 
(kg) (kg) (kg) 
Lighter-boned (LB) 
p+l 6.24 0.30 0.28y* 0.035 0.40 0.034 
RP2 6.23 0.21 0.34x 0.035 0.47 0.034 
p-3 6.41 0.22 0.28y 0.034 0.45 0.034 
Heavier-boned 
(HB) 
P+ 6.92 0.44 0.36a* 0.033 0.51 0.032 
RP 7.12 0.39 0.35a 0.034 0.51 0.032 
P- 6.85 0.20 0.25b 0.032 0.45 0.032 
Values are means and standard errors of six individually housed pigs. Average daily weight 
gain and average daily feed intake were analyzed using initial BW as a covariate. 
a,b Means without a common superscript in the same column are different (P<0.01). 
x,y Means without a common superscript in the same column are different (P<O. l ). 
*Means between sire lines in the same column are different (P<O.l). 
1 Phosphorous adequate diet 
2 Phosphorous repletion diet 
3 Phosphorous deficient diet 
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Table 3. Effect of genetic background and diet on plasma indicators of phosphorus status. 
Initial Week 1 Week2 
PIP4 Ca5 AKP6 PIP Ca AKP PIP 
(mg/L) (mM) (U/L) (mg/L) (mM) (U/L) (mg/L) 
Lighter-boned (LB) 
p+l 76 3.37 117 71 a 3.17 67b 83a 
(4.3) (0.05) (10.3) (5 .9) (0.04) (5.8) (4.6) 
RP2 80 3.43 116 5lb 3.20 84a 763 
(4.0) (0.12) (10.3) (3.5) (0.06) (5.8) (3.2) 
p_3 78 3.18 116 44b 3.23 84a 53b 
(2.5) (0.10) (10.3) (5.0) (0.01) (5.8) (6.3) 
Heavier-boned (HB) 
P+ 74 3.39 100 65
3 3.23 64b 83a 
(5.3) (0.06) (10.2) (3.4) (0.05) (5.6) (3.1) 
RP 74 3.27 99 
44b 3.28 753 8?3 
(3.4) (0.06) (10.2) (2.7) (0.03) (5.6) (2.3) 
P- 70 3.35 91 
39b 3.02 83a 5l b 
(4.9) (0.04) (10.2) (2.8) (0.1 6) (5.6) (4.5) 
Values are means and (standard errors) of six individually housed pigs. 
a,b Means without a common superscript in the same column are different (P<0.01). 
1 Phosphorous adequate diet 
2 Phosphorous repletion diet 
3 Phosphorous deficient diet 
4 Plasma inorganic phosphorous 
5 Plasma calcium concentration 
6 Alkaline phosphatase activity 
Ca 
(mM) 
3.63 
(0.29) 
3.37 
(0.08) 
3.41 
(0.12) 
3.61 
(0.15) 
3.43 
(0.09) 
3.40 
(0.05) 
AKP 
(U/L) 
77b 
(8.2) 
76b 
(8.2) 
11 43 
(8.2) 
80b 
(8.0) 
72b 
(8.0) 
111 a 
(8.0) 
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Table 4. Genetic background and dietary phosphorus influence bone strength and ash 
percentage. 
Body Weight Radial Metacarpal 
Final SE Strength SE Ash% SE 
(kg) (kN) 
Lighter-boned (LB) 
P+I 10.13 0.53 0.477a 0.0258 37.1 a 0.78 
RP2 10.93 0.24 0.429b 0.0250 34.8b 0.76 
p-3 10.34 0.39 0.253c* 0.0254 27.8c 0.77 
Heavier-boned (HB) 
P+ 11.97 0.78 0.576a 0.0281 36.9a 0.80 
RP 12.02 0.62 0.498b 0.0269 33.4b 0.80 
P- 10.36 0.52 0.319c* 0.0254 26.4c 0.77 
Values are means and standard errors of six individually housed pigs. 
a, b, c Means without a common superscript in the same column are different (P<O.O 1 ). 
* Means between sire lines are different (P<0.1 ). 
1 Phosphorous adequate diet 
2 Phosphorous repletion diet 
3 Phosphorous deficient diet 
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N=6. Means within sire line columns not sharing a common letter are significantly different (P<0.11 ). 
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N=6. No significant differences. However, there was a trend of increased OXI'R expression in the P- pigs when compared to the 
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FIG. 6. Genetic background and dietary phosphorus influence interleukin-6 gene expression in young pigs. 
N=6. No significant differences. However, in the HB line, there was a trend of increased IL6 expression in the P- pigs when 
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CHAPTER 4: MAPPING AND ASSOCIATION STUDIES OF GENES WHOSE 
EXPRESSION IS AFFECTED BY THE INTERACTION BETWEEN 
NUTRITION AND GENETIC BACKGROUND 
A paper to be submitted to Animal Genetics 
Laura J. Hittmeier1,2, Laura Grapes', Max F. Rothschild', Chad H. Stahl1'3 
Abstract 
Phosphorous (P) is essential to bone growth and maintenance; however, little 
research has focused on the genetic mechanisms controlling P utilization. Understanding the 
interactions between genetics and dietary P that optimize bone integrity could provide novel 
interventions for osteoporosis. Thirty-six pigs from two sire lines known to differ in bone 
structure (heavier-boned, HB, and lighter-boned, LB) were assigned to three diets (P 
adequate, P repletion, or P deficient) for 2 wks to examine the interaction of P nutrition and 
genetic background on bone integrity and growth performance. Previously, we observed 
that the interaction between nutrition and genetic background has an effect on the amount of 
calcitonin receptor (CALCR), vitamin D receptor (VDR), and insulin-like growth factor 
binding protein 3 (IGFBP3) message in the bone marrow of these pigs. 
In this study, single nucleotide polymorphisms (SNPs) were identified in CALCR, 
VDR, IGFBP3, and oxytocin receptor (OXTR) genes. These polymorphisms were found to 
be associated with several growth performance measurements, including feed:gain, average 
daily feed intake, and average daily gain. Most interestingly, the CALCR Banll 
1 Department of Animal Science and Center for Integrated Animal Genomics, Iowa State 
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2 Primary researcher and author. 
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polymorphism showed significant associations with both bone density and bone strength. In 
addition, linkage analysis of the VDR HpyCH4IV polymorphism in the Berkshire x 
Yorkshire intercross family mapped VDR to pig chromosome 5q. 
Introduction 
Currently, in the U.S. alone, 10 million individuals suffer from osteoporosis and an 
additional 34 million have been diagnosed with low bone mass, placing them at increased 
risk for this disease (National Institutes of Health 2003). Osteoporosis is characterized by a 
decrease in bone mineral density (BMD) and deterioration of the microarchitecture of bone, 
both of which result in increased susceptibility to fractures . Over 1.5 million fractures are 
attributed to osteoporosis annually, including 300,000 hip fractures, 700,000 vertebral 
fractures, 250,000 wrist fractures, and more than 300,000 fractures at other sites (National 
Institutes of Health 2003). These injuries translate into enormous medical expenses, with an 
estimated national direct expenditure (hospitals and nursing homes) of $14 billion each year 
for osteoporosis and related fractures (National Institutes of Health 2003). Because of the 
aging of the populous, the number of annual fractures and their associated costs could 
double or triple by the year 2020 (Riggs & Melton 1995; Looker et al. 1997). 
Bone mineral density (BMD) is a useful marker for risk of fracture, since it can be 
easily determined non-invasively. Bone mineral density is a highly heritable trait (Smith et 
al. 1973; Cummings et al. 1993; Ferrari et al. 1998; Nordstrom & Lorentzon 1999). 
However, the basis for the genetic variation seen in BMD is largely unknown. In humans, 
genetic linkage studies (Johnson et al. 1997; Devoto et al. 1998) and candidate gene 
association studies (Uitterlinden et al. 1998; Yamada et al. 2001) have implicated several 
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loci and candidate genes in the regulation of bone mass and the pathogenesis of osteoporotic 
fractures. Based on their roles in bone growth and development, genes of particular interest 
include calcitonin receptor (CALCR), vitamin D receptor (VDR), insulin-like growth factor 
binding protein 3 (JGFBP 3), and oxytocin receptor ( OXTR). Based on our previous work 
(Hittmeier et al. 2005), the interaction between nutrition and genetic background has an 
effect on the amount of CALCR, VDR and IGFBP 3 message in the bone marrow. 
Differences in growth rate, bone integrity, and gene expression within the bone marrow 
suggest a difference in the homeorhetic control of P utilization between these genetic lines. 
Understanding these differences could lead to novel treatments for osteoporosis and aid in 
the development of tests for identifying those at risk for this disease. 
The objective of this study was to identify single nucleotide polymorphisms (SNPs) 
in these genes and determine if these SNPs are associated with growth performance, bone 
density, and bone strength. Additionally, for genes not previously mapped in the pig 
genome, their chromosome positions were determined. 
Materials and Methods 
Phosphorous Study Animals 
All animal protocols were approved by Iowa State University' s Committee on 
Animal Care. Thirty-six female piglets of two genetic lines were obtained by crossing two 
sire lines with a single female line. These two sire lines are known to differ in bone 
structure, with one considered heavier-boned (HB) and the other considered lighter-boned 
(LB). At 28 d of age, animals were assigned to one of three treatments which consisted of 
being fed a P adequate diet (P+, 0.41 % P Available) , a P deficient diet (P-, 0.14% P Available) , or the 
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P deficient diet for 7d followed by the P adequate diet for 7d (P repletion diet, RP). Body 
weights were determined initially and weekly throughout the trial and average daily gain 
was calculated for each week individually and for the two week trial period. Individual feed 
consumption was recorded weekly and used to calculate feed to gain ratio for each week and 
across the trial period. 
At day 0, day 7, and day 14 of the study, venous blood samples were collected as 
described by Hittmeier et al. (2005). Plasma was obtained by centrifugation and stored at -
20°C until used for analysis. Calcium concentration, alkaline phosphatase activity (ALP), 
and inorganic phosphorous concentration (PIP) were determined for all plasma samples as 
described previously (Hittmeier et al. 2005; Bowers & McComb 1966; Gomori 1942). On 
day 14 of the study, all animals were euthanized by captive bolt. Intact radial and 
metacarpal bones were collected, and bone marrow samples were collected from the right 
humerus. In order to measure specific transcript levels, RNA was isolated from bone 
marrow, cDNA was synthesized, and semi-quantitative real-time PCR was performed as 
described previously (Hittmeier et al. 2005). Within one week following sacrifice of the 
animals, the radii were manually cleaned of all soft tissue and tested for tensile strength 
using a 5kN Flexure Fixture, as described previously (Hittmeier et al. 2005). 
PCR amplification of pig CALCR, VDR, IGFBP 3, and OXTR 
Genomic DNA was isolated from liver tissue using the DNeasy Tissue Kit (Qiagen) 
and sections of CALCR, VDR, IGFBP3, and OXTR genes were amplified by PCR using a 
PTC-2000 thermocycler (MJ Research, Waltham, MA). Primer pairs were designed based 
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on pig sequences (Table 1 ), and amplifications were performed using 40 ng of genomic 
DNA and Taq DNA polymerase (Invitrogen Life Technologies, Carlsbad, CA, USA). 
Sequencing and Polymorphism Identification 
Pooled PCR products from two different pig breeds were sequenced for each gene, 
using an ABI 3100 Genetic Analyzer (Foster City, CA, USA). The sequences were 
assembled and compared using Sequencher software version 3.0 (Gene Codes, Ann Arbor, 
MI, USA) to identify SNPs. The CALCR, VDR, IGFBP3 , and OXTR polymorphisms were 
found within recognition sites of the restriction enzymes Banll, HpyCH4IV, BsaHl, and 
Aval, respectively, and the primer pairs indicated above were used to develop PCR 
restriction fragment length polymorphism (PCR-RFLP) tests. 
Resource Population for Linkage Mapping 
DNA samples were obtained from a Berkshire and Yorkshire (B x Y) pig breed 
intercross reference family from Iowa State University. The B x: Y reference family was 
created by crossing nine Yorkshire dams and two Berkshire boars to yield nine F 1 litters. 
From the F 1 litters, eight boars and 26 sows were mated to produce a total of 510 F 2 animals. 
This pedigree was originally utilized to map quantitative trait loci (QTL) for meat quality 
and growth and body composition traits using microsatellite markers (Malek et al. 2001), 
and the map contains over 175 gene markers. 
Chromosomal Assignment 
The VDR HpyCH4IV PCR-RFLP test was used to genotype the B x Y pig reference 
family. The VDR gene was mapped by linkage using two-point and multi-point analyses, 
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using CRIMAP version 2.4 (Green et al. 1990) together with genotypes from previous 
mapping studies in the B x Y reference family. 
The map position of OXTR was predicted based on synteny with the human gene 
location according to the human-pig comparative map (Goureau et al. 1996). The CALCR 
and IGFBP3 gene have been mapped previously (Zolnierowicz et al. 1994; Nielsen & 
Larsen 1997). 
Statistical Analysis 
Association analyses between the CALCR Banll, VDR HpyCH4IV, JGFBP3 Bsam, 
and OXTR Aval polymorphisms and 15 traits, as well as gene expression levels, in the P 
study animals were performed using the SAS mixed model procedure (SAS Institute), with a 
model that included sire line, treatment diet, the interaction between sire line and treatment 
diet, marker genotype and the interaction between marker genotype and treatment diet as 
fixed effects. Sow nested within sire line was fit as the random effect. For average daily 
gain and average daily feed intake measured at week 1, 2 and over the course of the feeding 
trial, initial body weight was fit as a covariate in the model. For the traits bone density and 
bone strength, body weight at week 2 was fit as a covariate in the model. 
Results 
Linkage Analysis 
Linkage analysis of the VDR HpyCH4IV polymorphism in the intercross mapped 
VDR to pig chromosome Sq. Significant linkages of the VDR polymorphism were observed 
with IGFI (recombination fraction= 0.04 and LOD = 30.26), SW2 (recombination fraction 
= 0.18 and LOD = 3.72), SW904 (recombination fraction= 0.13 and LOD = 16.94), and 
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SW995 (recombination fraction= 0.11 and LOD = 14.09). The best map order of the VDR 
gene produced by multi-point analysis with other linked markers was (distance in Kosambi 
cM): SW2-24.9-SW904-10.3-VDR-3.4-IGFJ-7.0-SW995. 
Association Analysis 
An HpyCH4IVPCR-RFLP was identified in intron 8 of the VDR gene. Digestion of 
the 402 bp PCR product resulted in fragments of 279 bp and 123 bp (allele 1) or 185 bp, 123 
bp, and 94 bp (allele 2). Association analysis in the P study pigs detected significant 
genotype effects of the VDR HpyCH4IV polymorphism on initial plasma inorganic 
phosphorous levels (PIP), PIP at wk 2, and average daily feed intake (ADFI) at wk 1. 
Association analysis also detected significant genotype by treatment interactions of the VDR 
HpyCH4IV polymorphism on feed:gain ratio (wk 2 and cumulative), PIP at wk 1, average 
daily weight gain (ADG) at wk 2, and ADFI wk 2. 
An Aval PCR-RFLP was identified in exon 4 of the OXTR gene. Digestion of the 
928 bp PCR product resulted in fragments of 928 bp (allele 1) or 781 and 147 bp (allele 2). 
Only 3 animals had the 11 genotype, so the association analysis only compared the 12 
genotype animals to the 22 genotype animals. Association analysis detected significant 
genotype by treatment interactions of the OXTR Aval polymorphism on PIP (wk 2), ADG 
(wk 2 and cumulative), and ADFI (wk 2 and cumulative). 
A Bsam PCR-RFLP was identified in intron 2 of the JGFBP3 gene. Digestion of 
the 438 bp PCR product resulted in fragments of 438 bp (allele 1) or 326 and 112 bp (allele 
2). Association analysis detected significant genotype effects of the IGFBP 3 Bsam 
polymorphism on PIP (initial and wk 1 ). Association analysis also detected significant 
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genotype by treatment interactions of the IGFBP3 polymorphism on feed: gain (wk 2 and 
cumulative). 
A Banll PCR-RFLP was identified in intron 12 of the CALCR gene. Digestion of the 
477 bp PCR product resulted in fragments of 477 bp (allele 1) or 332 and 145 bp (allele 2). 
This CALCR Banll polymorphism was not segregating in the heavier-boned line (17 animals 
had 22 genotype, 1 animals had 12 genotype), so the association analysis was only 
performed within the lighter-boned line. Association analysis revealed significant genotype 
effects of the CALCR Banll polymorphism on feed:gain (wk 2 and cumulative), PIP (wk 1), 
ADG (wk 2), bone strength. There was also a trend for a genotype effect on bone density 
(Table 2). Association analysis also revealed significant genotype by treatment interactions 
of the CALCR polymorphism on feed:gain (wk 2 and cumulative) and bone strength (Table 
3). 
Discussion 
The assignment of VDR to porcine chromosome 5q is in accordance with 
localization of human VDR to position 12ql2-q14 since comparative mapping studies have 
shown that pig chromosome 5 shares homology with human chromosome 12q (Goureau et 
al. 1996). The results presented here extend the linkage group on pig chromosome 5 and are 
in accordance with conserved synteny between human chromosome 12. The VDR gene was 
mapped to position 108.0 cM, 3.4 cM from the JGFI gene, which was previously mapped to 
chromosome 5 (Wintero et al. 1994). 
The map position of JGFBP3 and CALCR in the pig genome have been determined 
previously; CALCR was mapped to 9ql 1-q1 2 (Zolnierowicz et al. 1994) and IGFBP3 was 
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mapped to 18q24 (Nielsen & Larsen 1997). The map position of OXTR was predicted based 
on synteny with the human gene location according to the human-pig comparative map. 
Thus, the predicted location of OXTR in the pig genome is the q arm of chromosome 13. 
In the P study animals, the VDR HpyCH4IV, OXTR Aval, IGFBP3 BsaHl, and 
CALCR BanII polymorphisms were all found to be associated with several growth 
performance traits. The VDR HpyCH4IV polymorphism had significant associations with 
growth performance traits, such as average daily gain (ADG) and feed: gain. The 22 
genotype appears to be the least favorable one in cases of P deficiency, with lower ADG at 
wk 2 than the 11 animals (P<0.07) and higher feed:gain at wk 2 and cumulative than the 11 
or 12 pigs (P<0.10). However, the 22 animals under P deficiency did have higher PIP at wk 
1 than the 11or12 animals (P<0.002 and P<0.05, respectively). In cases of adequate P, the 
11 genotype appears to be the least favorable with higher feed:gain at wk 2 than the 12 or 22 
pigs (P<0.04 and P<0.06, respectively) and higher feed:gain overall than the 12 pigs 
(P<0.10). In fact, the 11 animals with adequate P had lower ADG (P<0.10) and higher 
feed:gain (P<0.09) at wk 2 than the P deficient 11 animals, and the 11 animals also tended to 
have lower PIP initially and at wk 2 than the 12 or 22 animals. In cases of P repletion, the 
12 animals had higher ADFI at wk 2 than the 11 animals (P<0.07). 
The OXTR Aval polymorphism also had significant associations with many growth 
performance traits. In cases of adequate P, the 12 genotype appears to be more favorable 
than the 22 genotype. The 12 animals had greater PIP at wk 2 (P<0.08), ADG at wk 2 and 
cumulative (P<0.02 and P<0.07, respectively), and ADFI at wk 2 and cumulative (p<0.01 
and P<0.07, respectively). 
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In this study, the IGFBP 3 Bsam polymorphism had significant associations with 
feed: gain and PIP. In cases of P deficiency, pigs with the 11 genotype appear to be the least 
efficient. They had a greater feed:gain at wk 2 and overall than the 12 animals (P<0.03). 
Regardless of treatment, pigs with the 11 genotype had greater PIP levels initially and at wk 
1 than 22 animals (P<0.008). In cases of adequate P, the 22 allele appears to be the least 
favorable. These animals had greater feed:gain at wk 2 and overall than the 11 or 12 
animals (P<0.07). These data indicate that many of these traits are influenced by the 
interaction between IGFBP3 Bsam genotype and diet. 
In the lighter-boned line, the CALCR Banll polymorphism had significant 
associations with several growth performance traits and radial bone strength. The 11 
animals had higher PIP at wk 1 (P<0.05) than the other genotypes, and they also tended to 
have greater bone density than the other two genotypes. The 12 animals had significantly 
higher ADG in wk 2 than the 11 or 22 genotype animals (P<0.09 and P<0.02, respectively). 
In cases of P deficiency, the 22 genotype led to higher feed:gain at wk 2 and overall than the 
11 and 12 genotype (P<0.008 and P<0.003, respectively) as well as greater bone strength 
than the 11 or 12 genotype (P<0.02). Interestingly, the 22 animals were able to maintain 
their bone strength under P deficiency at the same level as the P adequate 22 animals; 
however, the 22 repletion diet animals tended to have lower bone strength than the P 
adequate 22 animals (P<O. l ). Also, even though the 11 animals had the lowest bone 
strength under P deficiency, they were best able to regain their bone strength under the 
repletion diet and actually had significantly greater bone strength than the 12 animals 
(P<0.05). 
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Polymorphisms in the human CALCR and VDR that are associated with bone mineral 
density and osteoporosis have been identified (Masi et al. 1998; Tsai et al. 2003; Zhao et al. 
2003; Grundberg et al. 2003; Chen et al. 2003; Yamada et al. 2003). By examining these 
genes in the pig, this study has provided further incentive for the use of pigs as the premier 
animal model for bone studies. 
Based on previous research in our lab, the expression of CALCR, VDR, and JGFBP 3 
in the bone marrow is affected by the interaction between diet (P deficiency) and genetic 
background. In this study, SNPs were identified in CALCR, VDR, JGFBP3, and OXTR for 
association studies in swine. The results reported here suggest associations among the 
polymorphisms in the CALCR, VDR, IGFBP3, and OXTR genes and several growth 
performance measurements, including feed:gain, average daily feed intake, and average 
daily gain. Most interestingly, the CALCR Banll polymorphism showed significant 
associations with bone strength. Further study may be useful to promote understanding of 
the genetic background x diet interactions that were observed in our previous work 
(Hittmeier et al. 2005). 
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Table 1. Primers designed to amplify CALCR, VDR, IGFBP-3, and OXTR gene fragments 
Gene Name 
Calcitonin Receptor (CALCR) 
Vitamin D Receptor (VDR) 
Primer sequences for PCR (5'-3') 
1-TTCTCCTCGCCTGCCTTC 
11-TCTGCCTGACACTGAACCAT 
1-ACCAGATCGTGCTGCTGAAG 
11-GGGAGACGATGCAGATGG 
GenBank Annealing 
Accession No. Temp. (°C) 
NM 214354 55.5 
AJ606306 60 
Source 
·--------------------- ---------- ---------------------------------- --- ---- -------------- --------- --------------- -- ---------------------------------------------- -------
Insulin-like growth factor binding 1-CAAGTCTCAAGCACGGACAC A Y464121 57 Mote et al. 2004 
protein 3 (IGFBP3) 11-GCCAGGGGCTCTCTCTTTT 
---------------------------------------------------------------------------------------------------------------------------------------------------------------------
Oxytocin Receptor (OXTR) 1-CTGCAACCCCTGGATCTACA 
II-A TTTTTCTTTCCCAACTGCTTC 
X71796 53.5 
-....) 
....... 
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Table 2. Effect of CALCR genotypes on bone density in the lighter-boned line. 
Genotype Bone Density (g/mL) a SE 
11 1.154 0.016 
12 1.098 0.015 
22 1.119 0.015 
Values are means and standard errors. 
a Fresh weight of the metacarpal and the volume of water that it displaced. 
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Table 3. Effect of CALCR genotypes on radial bone strength in the lighter-boned line. 
Bone Strength (kN) 
Genotype p+I RP2 p-3 
11 0.48 (0.04t o.51 co.o5t 0.16 co.o5t 
12 0.48 (0.06)a 0.31 (0.05)b 0.24 (0.03)a 
22 0.50 (0.04)a 0.41 (0.04)ab 0.49 (0.06)b 
Values are means and (standard errors). Within one week following sacrifice of the animals, 
the radii were manually cleaned of all soft tissue and tested for tensile strength using a 5kN 
Flexure Fixture, configured for three-point bend tests, attached to an Instron Universal 
Testing Machine Model 4502 equipped with a 10 kN load cell (Instron Corporation, Canton, 
MA). Load applied at bone breaking was determined using Series IX, v 8.08.00 software 
(Instron Corporation). 
a,b Means without a common superscript in the same column are different (P<0.05). 
1 Phosphorous adequate diet 
2 Phosphorous repletion diet 
3 Phosphorous deficient diet 
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CHAPTER 5: GENERAL CONCLUSIONS 
General Discussion 
Differential gene expression, as well as altered growth performance under P 
deficiency, suggests a difference in the mechanisms of homeorhetic control of P between the 
genetic lines of pigs examined in these studies. The three most statistically significant 
changes in gene expression that were based on the interaction of dietary P deficiency and 
genetic background were seen in calcitonin receptor (CALCR), vitamin D receptor (VDR), 
and insulin-like growth factor binding protein 3 (JGFBP 3). Single nucleotide 
polymorphisms (SNPs) were identified in these genes and were associated with several 
growth performance measurements, including feed:gain, average daily feed intake, and 
average daily weight gain. Most interestingly, the CALCR Banll polymorphism showed 
significant associations with bone strength. 
Osteoporosis is a multi-factorial skeletal disease that currently affects more than 10 
million Americans [1] . In order to better understand the mechanisms involved in this 
disease, appropriate animal models for human osteoporosis are urgently needed. Pigs are an 
excellent model for investigating the nutritional factors that may affect bone since the bone 
remodeling cycle in pigs is histologically similar to that of humans, but is more rapid, 
allowing relatively short experimental times. Pigs also possess a definable peak bone 
mass, closely resemble humans in their size, diet, gastrointestinal function, and estrous cycle 
[2-5]. Additionally, pigs are one of the few animal species in which spontaneous fractures 
have been reported [ 6] . 
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In conclusion, this research is an important step in the development of an animal 
model for human osteoporosis. We have begun to identify the mechanisms by which dietary 
P interacts with genetic background to affect BMD and bone integrity. This research is 
necessary because the lack of this knowledge is preventing the development of dietary 
intervention strategies for the prevention of osteoporosis. Understanding the interaction 
between nutrition and genotype could lead to novel treatments for osteoporosis and aid in 
the development of tests for identifying those at risk before peak BMD has been achieved. 
With a better understanding of its effect on bone, dietary P requirements could be more 
precisely defined, and we may be able to identify human populations that have different 
dietary requirements in order to optimize their BMD and prevent osteoporosis. This new 
knowledge could also lead to genotype-specific dietary intervention strategies which will 
likely be more effective in reducing the incidence of osteoporosis. 
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